Rare central precocious puberty

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

5 events
Apr 2023

Lupron Depot-Ped: FDA approved

treatment of pediatric patients with central precocious puberty (CPP)

FDAcompleted
Jun 2017

Triptodur: FDA approved

Treatment of pediatric patients 2 years of age and older with central precocious puberty

FDAcompleted
May 2007

Supprelin LA: FDA approved

Treatment of central precocious puberty

FDAcompleted
Feb 1992

Synarel Nasal Solution: FDA approved

Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.

FDAcompleted
Dec 1991

Supprelin Injection: FDA approved

Treatment of central precocious puberty.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

3 programs

FINANCIAL LANDSCAPE SUMMARY

3

Total programs

3

Open now

3

Copay cards

Copay Assistance3

Lupron Depot

AbbVie Inc.

OpenContact for detailsApply ↗

Supprelin Injection

Roberts Pharmaceutical Corp.

OpenContact for details

Synarel Nasal Solution

Syntex (USA), Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

5 FDA-approved

Lupron Depot-Ped

(Leuprolide acetate)Orphan drug

AbbVie Endocrine Inc.

12.1 Mechanism of Action Leuprolide acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion (LH and follicle stimulating hormone...

Approved Apr 2023FDA label ↗

Triptodur

(triptorelin pamoate)Orphan drug

Arbor Pharmaceuticals, LLC

12.1 Mechanism of Action Triptorelin is a GnRH agonist.

Approved Jun 2017FDA label ↗

Supprelin LA

(Histrelin)Orphan drug

Endo Pharmaceuticals Solutions, Inc.

12.1 Mechanism of Action SUPPRELIN LA is a GnRH agonist and an inhibitor of gonadotropin secretion when given continuously. It delivers approximately ...

Approved May 2007FDA label ↗

Synarel Nasal Solution

(Nafarelin acetate)Orphan drug

Syntex (USA), Inc.

Approved Feb 1992FDA label ↗

Supprelin Injection

(Histrelin acetate)Orphan drug

Roberts Pharmaceutical Corp.

12.1 Mechanism of Action SUPPRELIN LA is a GnRH agonist and an inhibitor of gonadotropin secretion when given continuously. It delivers approximately ...

Approved Dec 1991FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Rare central precocious puberty.
Search all trials →
Search clinical trials for Rare central precocious puberty

Recent News & Research

No recent news articles indexed yet for Rare central precocious puberty.
Search PubMed for Rare central precocious puberty

Browse all Rare central precocious puberty news →

Specialist Network

No specialists currently listed for Rare central precocious puberty.

View all Rare central precocious puberty specialists →

Quick Actions